How did Bristol-Myers Squibb's (BMY) revenue perform in Q2 2010 compared to Q2 2009?

BMY's net sales increased by 2% to $4.77 billion in the second quarter of 2010, up from $4.67 billion in the same period of 2009. This growth was driven by higher U.S. sales of key products like PLAVIX* and continued demand for products such as BARACLUDE, ABILIFY*, and SPRYCEL in international markets.

What is the expected impact of U.S. healthcare reform on BMY?

The U.S. healthcare reform legislation enacted in March 2010 is expected to have a significant negative financial impact on BMY. This includes increased minimum rebates on Medicaid drug sales (retroactive to Jan 1, 2010), extended rebates to Medicaid managed care plans, discounts for Medicare Part D 'Donut Hole' participants starting in 2011, and an annual non-tax deductible fee based on market share. The company anticipates the impact in 2011 will be approximately double the impact expected in 2010.

What are the key product developments or pipeline advancements highlighted in this report?

BMY reported positive developments across several late-stage pipeline candidates. Notably, ONGLYZA and dapagliflozin showed promising results in diabetes trials. Significant progress was also highlighted for SPRYCEL in leukemia and ipilimumab in melanoma. Apixaban, an anticoagulant, also demonstrated efficacy in Phase III trials. The company is working with the FDA on belatacept for organ transplant rejection, which received a complete response letter requesting additional data.

What are the major risks or challenges facing BMY, as indicated in this filing?

The most significant upcoming challenge is the expected loss of exclusivity for PLAVIX* in the U.S. within two years, which is anticipated to cause a rapid and precipitous decline in sales and profitability. Additionally, ongoing patent litigations for key products like PLAVIX* and ABILIFY* present uncertainty regarding future generic competition. The increasing costs associated with healthcare reform and potential pricing pressures in international markets also pose risks.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY2010

Summary

Bristol-Myers Squibb Company (BMY) reported solid financial results for the second quarter and first half of 2010. Net sales increased year-over-year driven by strong performance in key products like PLAVIX* in the U.S. and growth in various international markets for products such as BARACLUDE, ABILIFY*, and SPRYCEL. The company also saw an increase in diluted earnings per share from continuing operations, partly due to a reduction in outstanding shares following the Mead Johnson split-off. Despite these positives, the company faces significant headwinds, most notably the upcoming loss of exclusivity for its largest product, PLAVIX*, in the U.S., which is expected to materially impact future sales and profitability. Additionally, the recently enacted U.S. healthcare reform legislation will lead to increased rebate obligations and other costs, further pressuring margins. Management is actively pursuing a "string-of-pearls" strategy focused on strategic acquisitions and licensing to build a robust pipeline and mitigate the impact of patent expirations.

Financial Highlights

57 data points

Beta

Revenue

$4.77B

0.7% Gross Margin

Net Income

$927.00M

0.2% Net Margin

EPS (Diluted)

$0.53

Total Assets

$31.05B

Cash & Equivalents

$5.92B

Free Cash Flow

$968.00M

Financial Statements

Beta

Revenue	$4.77B
Cost of Revenue	$1.28B
Gross Profit	$3.49B
R&D Expenses	$822.00M
SG&A Expenses	$894.00M
Operating Expenses	$3.18B
Operating Income	$927.00M
Interest Expense	$32.00M
Net Income	$927.00M
EPS (Basic)	$0.54
EPS (Diluted)	$0.53
Shares Outstanding (Basic)	1.72B
Shares Outstanding (Diluted)	1.73B

Key Highlights

1Net sales increased by 2% to $4.77 billion for the three months ended June 30, 2010, and by 7% to $9.58 billion for the six months ended June 30, 2010, compared to the prior year periods.
2Diluted Earnings Per Share (EPS) from continuing operations attributable to BMS increased to $0.53 for the three months and $0.96 for the six months ended June 30, 2010, up from $0.44 and $0.77, respectively, in the prior year.
3The company divested its manufacturing operations in Latina, Italy, as part of its ongoing Productivity Transformation Initiative (PTI) aimed at achieving $2.5 billion in annual cost savings.
4Significant R&D progress was highlighted, including positive Phase III study results for ONGLYZA (diabetes), dapagliflozin (diabetes), ORENCIA (rheumatoid arthritis), SPRYCEL (leukemia), apixaban (anticoagulant), and ipilimumab (melanoma).
5PLAVIX* sales in the U.S. increased primarily due to higher average selling prices, while international sales continued to be impacted by generic competition.
6The company is actively managing its product portfolio and pipeline, balancing investments in late-stage development with cost management strategies.
7U.S. healthcare reform legislation is expected to negatively impact the company through increased Medicaid rebates and other costs, with an estimated doubling of impact in 2011 compared to 2010.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2010

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions